Sector News

ICON and LEO Pharma join forces on clinical trial mission

March 11, 2023
Life sciences

LEO Pharma – a company that focuses on medical dermatology – and ICON have announced a partnership that will enable LEO Pharma to scale clinical trial delivery that is both patient-centric and cost-effective.

The collaboration will also support the company’s wider ambition of building one of the most efficient and effective clinical portfolio in the industry.

In addition, it is hoped that it will improve the lives of dermatology patients with further access to innovative clinical trials and the launch of new medicines. The partnership will operate under the acronym of PACE – reflecting the need to move quickly in order to address modern clinical development challenges.

The name also represents LEO Pharma and ICON’s shared values – Passion, Agility, Communication and Excellence in delivery.

Steve Cutler, CEO at ICON, has high hopes for the partnership: “ICON is delighted to enter this partnership with LEO Pharma that truly takes advantage of our breadth of capability and expertise. We take a flexible and integrated approach when working with our partners, utilising fully outsourced, hybrid and FSP models that complement our partner’s internal capabilities and enable them to achieve their strategic goals.

He added: “It is also motivating for our employees to be working with a partner that shares our values and has a commitment to improving the lives of patients.”

Jörg Möller, Executive Vice President and head of Global R&D at LEO Pharma, explained: “We’ve been exploring several outsourcing models but found a hybrid sourcing model to be the most efficient. Partnering with ICON supports our 2030 strategy as it will help us to bring innovative treatments to patients faster while also supporting a more sustainable business through scalability and flexibility.”

“ICON’s wealth of services and leading position in clinical development will support LEO Pharma’s R&D strategy building on driving innovation through partnerships and support staying competitive,” he concluded.

by John Pinching

Source: pharmatimes.com

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach